Jorge Sérgio Reis‐filho

Jorge Sérgio Reis‐filho's AcademicInfluence.com Rankings

Philosophy

#3496

World Rank

#5639

Historical Rank

Logic

#1195

World Rank

#1881

Historical Rank

philosophy Degrees

Jorge Sérgio Reis‐filho

Biology

#4385

World Rank

#6544

Historical Rank

Pathology

#47

World Rank

#107

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Jorge Sérgio Reis‐filho's Degrees

Doctorate Medicine University of Porto
PhD Pathology University of Porto

Why Is Jorge Sérgio Reis‐filho Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jorge Sérgio Reis‐filho's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. (2015) (1875)
International network of cancer genome projects (2010) (1839)
Triple-negative breast cancer. (2010) (1781)
The landscape of cancer genes and mutational processes in breast cancer (2012) (1610)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF (2010) (1366)
Resistance to therapy caused by intragenic deletion in BRCA2 (2008) (933)
Triple negative tumours: a critical review (2007) (919)
Basal-like breast cancer: a critical review. (2008) (910)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer (2015) (844)
COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES (2009) (839)
Breast cancer prognostic classification in the molecular era: the role of histological grade (2010) (749)
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. (2010) (698)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. (2014) (684)
Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype (2005) (667)
Gene expression profiling in breast cancer: classification, prognostication, and prediction (2011) (658)
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. (2010) (631)
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists (2011) (629)
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. (2012) (610)
BRCA1 dysfunction in sporadic basal-like breast cancer (2007) (609)
Oncogenic Braf induces melanocyte senescence and melanoma in mice. (2009) (534)
Molecular evolution of breast cancer (2005) (532)
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma (2015) (523)
Germline mutations in RAD51D confer susceptibility to ovarian cancer (2011) (493)
Basal-like breast cancer and the BRCA1 phenotype (2006) (486)
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes (2009) (473)
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade (2010) (457)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020) (432)
Histological types of breast cancer: How special are they? (2010) (429)
Histological and molecular types of breast cancer: is there a unifying taxonomy? (2009) (419)
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe (2017) (408)
Genetic heterogeneity and cancer drug resistance. (2012) (398)
Genetic Interactions in Cancer Progression and Treatment (2011) (397)
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants (2019) (397)
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets (2009) (385)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. (2010) (362)
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast (2006) (357)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. (2018) (348)
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival (2007) (331)
Functionally Recurrent Rearrangements of the MAST Kinase and Notch Gene Families in Breast Cancer (2011) (330)
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation (2011) (325)
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients (2008) (321)
Breast cancer precursors revisited: molecular features and progression pathways (2010) (307)
Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma (2011) (305)
Phyllodes tumours of the breast: a consensus review (2016) (305)
Basal-like breast carcinomas: clinical outcome and response to chemotherapy (2006) (297)
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor (2013) (291)
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (288)
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. (2002) (284)
FGFR1 Emerges as a Potential Therapeutic Target for Lobular Breast Carcinomas (2006) (280)
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis (2007) (273)
Columnar Cell Lesions of the Breast: The Missing Link in Breast Cancer Progression?: A Morphological and Molecular Analysis (2005) (270)
Breast cancer intra-tumor heterogeneity (2014) (258)
High Frequency of Coexistence of Columnar Cell Lesions, Lobular Neoplasia, and Low Grade Ductal Carcinoma In Situ With Invasive Tubular Carcinoma and Invasive Lobular Carcinoma (2007) (255)
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer (2009) (254)
Emerging therapeutic targets in endometrial cancer (2011) (254)
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (252)
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. (2004) (250)
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. (2014) (243)
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors (2010) (243)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. (2018) (239)
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer (2007) (238)
Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray (2003) (232)
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2014) (229)
Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis (2007) (227)
Morphologic and Molecular Evolutionary Pathways of Low Nuclear Grade Invasive Breast Cancers and Their Putative Precursor Lesions: Further Evidence to Support the Concept of Low Nuclear Grade Breast Neoplasia Family (2008) (226)
The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special type (2010) (225)
Progression from ductal carcinoma in situ to invasive breast cancer: Revisited (2013) (220)
Analysis of PALB2/FANCN-associated breast cancer families (2007) (219)
Combinatorial biomarker expression in breast cancer (2010) (217)
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer (2012) (213)
Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis (2009) (212)
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray‐based CGH analysis (2009) (207)
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival (2016) (205)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment (2010) (196)
Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue (2008) (190)
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas (2010) (183)
Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity (2005) (181)
Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers (2009) (181)
Next-generation sequencing (2009) (180)
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands (2014) (178)
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers (2010) (173)
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. (2019) (172)
Salivary gland-like tumours of the breast: surgical and molecular pathology (2003) (171)
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations (2011) (170)
Circulating tumour cells and cell-free DNA as tools for managing breast cancer (2013) (168)
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis (2005) (168)
Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis (2006) (167)
Patient-derived xenograft (PDX) models in basic and translational breast cancer research (2016) (166)
FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo (2011) (164)
Whole genome sequencing of matched primary and metastatic acral melanomas. (2012) (161)
SF3B1 mutations constitute a novel therapeutic target in breast cancer (2014) (161)
p63 expression in normal skin and usual cutaneous carcinomas (2002) (158)
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer (2017) (156)
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes (2017) (156)
Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma (2007) (155)
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection (2012) (154)
PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas (2009) (153)
Functional viability profiles of breast cancer. (2011) (151)
Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. (2011) (151)
CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome (2008) (150)
Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. (2011) (148)
Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes (2004) (148)
Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype (2008) (145)
Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines (2008) (144)
Tackling the Diversity of Triple-Negative Breast Cancer (2013) (143)
Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type (2010) (143)
Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. (2015) (142)
The diagnosis and management of pre-invasive breast disease: Genetic alterations in pre-invasive lesions (2003) (141)
Are triple-negative tumours and basal-like breast cancer synonymous? (2007) (140)
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations (2014) (139)
In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2+ breast cancer (2015) (138)
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancers (2012) (137)
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data (2006) (136)
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer (2016) (136)
Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement (2011) (136)
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction (2011) (135)
The impact of expression profiling on prognostic and predictive testing in breast cancer (2006) (135)
Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. (2015) (135)
Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas (2009) (132)
The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. (2005) (131)
Novel and Classic Myoepithelial/Stem Cell Markers in Metaplastic Carcinomas of the Breast (2003) (130)
The diagnosis and management of pre-invasive breast disease: Pathology of atypical lobular hyperplasia and lobular carcinoma in situ (2003) (130)
A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. (2007) (128)
Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas) (2010) (128)
Genomic landscape of adenoid cystic carcinoma of the breast (2015) (128)
Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets (2009) (125)
Epithelial and Mesenchymal Subpopulations Within Normal Basal Breast Cell Lines Exhibit Distinct Stem Cell/Progenitor Properties (2012) (125)
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations (2014) (123)
Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas (2011) (123)
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. (2019) (123)
Challenges translating breast cancer gene signatures into the clinic (2012) (122)
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer (2009) (121)
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines (2013) (119)
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer (2017) (118)
Taking Advantage of Basic Research: p63 Is a Reliable Myoepithelial and Stem Cell Marker (2002) (118)
The Genomic Landscape of Male Breast Cancers (2016) (118)
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants (2016) (117)
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer (2012) (117)
Clinical and Biological Significance of E-cadherin Protein Expression in Invasive Lobular Carcinoma of the Breast (2010) (117)
Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry (2013) (117)
Tumor size and survival in breast cancer—a reappraisal (2010) (117)
Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis (2007) (116)
Polymorphous low‐grade adenocarcinoma of the salivary glands with transformation to high‐grade carcinoma (2002) (114)
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer (2007) (114)
β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast (2010) (112)
p63 Expression in Solid Cell Nests of the Thyroid: Further Evidence for a Stem Cell Origin (2003) (110)
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification (2015) (110)
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas (2017) (109)
Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. (2006) (108)
Going with the Flow: From Circulating Tumor Cells to DNA (2013) (107)
Biomarker studies: a call for a comprehensive biomarker study registry (2011) (107)
Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type (2009) (106)
The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. (2014) (106)
Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples (2017) (103)
Chromogenic and fluorescent in situ hybridization in breast cancer. (2007) (103)
The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. (2017) (101)
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. (2018) (99)
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. (2019) (99)
Identification of NTN4, TRA1, and STC2 as Prognostic Markers in Breast Cancer in a Screen for Signal Sequence Encoding Proteins (2007) (98)
Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas? (2000) (97)
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (97)
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast (2014) (96)
Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. (2019) (96)
HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. (2020) (96)
Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype (2007) (95)
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection (2020) (93)
Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry (2010) (92)
The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer (2015) (91)
Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue (2006) (91)
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients (2021) (91)
Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs (2020) (90)
Basal-like breast carcinoma: from expression profiling to routine practice. (2009) (90)
Salivary duct carcinomas can be classified into luminal androgen receptor‐positive, HER2 and basal‐like phenotypes * (2012) (90)
Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression (2016) (90)
Microarray-based Gene Expression Profiling as a Clinical Tool for Breast Cancer Management: Are We There Yet? (2009) (89)
Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? (2009) (89)
Processed pseudogenes acquired somatically during cancer development (2014) (87)
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer (2020) (87)
EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines (2009) (87)
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization (2006) (86)
Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. (2011) (86)
Molecular Profiling: Moving Away from Tumor Philately (2010) (86)
Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. (2015) (86)
Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers (2011) (86)
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. (2019) (83)
DICER1 hotspot mutations in non-epithelial gonadal tumours (2013) (83)
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers (2016) (83)
The molecular basis of breast cancer pathological phenotypes (2017) (82)
Diverse alterations associated with resistance to KRAS(G12C) inhibition (2021) (82)
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. (2016) (81)
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors (2020) (81)
Immunophenotypic and genomic characterization of papillary carcinomas of the breast (2012) (81)
Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. (2010) (80)
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. (2013) (80)
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer (2017) (79)
Uterine adenosarcomas are mesenchymal neoplasms (2016) (79)
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases (2017) (78)
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy (2020) (78)
Patho-biological aspects of basal-like breast cancer (2009) (78)
Genetic Alterations of Triple Negative Breast Cancer By Targeted Next Generation Sequencing And Correlation With Tumor Morphology (2016) (78)
Distribution and significance of 14‐3‐3σ, a novel myoepithelial marker, in normal, benign, and malignant breast tissue (2004) (78)
Aurora-A Regulation of Nuclear Factor-κB Signaling by Phosphorylation of IκBα (2007) (77)
Expression of c-met Tyrosine Kinase Receptor Is Biologically and Prognostically Relevant for Primary Cutaneous Malignant Melanomas (2003) (76)
Molecular characterisation of cell line models for triple-negative breast cancers (2012) (76)
MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast (2015) (76)
Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis (2008) (75)
Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein (2016) (75)
The role of molecular analysis in breast cancer (2009) (75)
The role of caveolin-1 in human breast cancer (2011) (75)
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (75)
A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines (2009) (75)
Mixed micropapillary–ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components (2009) (75)
Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy (2011) (75)
The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. (2007) (75)
The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. (2018) (74)
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer (2019) (74)
Getting it right: designing microarray (and not ‘microawry’) comparative genomic hybridization studies for cancer research (2007) (73)
TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers (2016) (73)
Molecular Classification of Estrogen Receptor-positive/Luminal Breast Cancers (2012) (72)
Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity (2018) (72)
Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival (2014) (71)
A mouse model of melanoma driven by oncogenic KRAS. (2010) (71)
A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks (2010) (70)
Breast cancer intratumor genetic heterogeneity: causes and implications (2012) (70)
Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy (2020) (70)
APRIN is a cell cycle specific BRCA2‐interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer (2012) (70)
Nestin is expressed in basal-like and triple negative breast cancers (2008) (70)
The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers (2010) (69)
Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival (2015) (69)
Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma (2009) (68)
Lymphangiogenesis in tumors: What do we know? (2003) (67)
Metastasis and immune evasion from extracellular cGAMP hydrolysis. (2020) (67)
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer (2016) (66)
Compromised BRCA1-PALB2 interaction is associated with breast cancer risk (2017) (66)
MYC amplification in breast cancer: a chromogenic in situ hybridisation study (2006) (66)
Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. (2007) (65)
PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study (2010) (65)
Functional characterization of the 19q12 amplicon in grade III breast cancers (2012) (65)
CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification (2010) (65)
A whole‐genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor‐negative and ‐positive breast cancers (2012) (65)
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib (2012) (65)
Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation (2007) (64)
Metaplastic breast carcinoma: more than a special type (2014) (64)
Hereditary breast cancer: from molecular pathology to tailored therapies (2008) (63)
the 11q13‐q14 amplicon: Clinicopathological correlations and potential drivers (2013) (63)
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer (2018) (63)
Maspin expression in myoepithelial tumors of the breast. (2001) (62)
Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression. (2019) (61)
Telomerase expression and proliferative activity suggest a stem cell role for thyroid solid cell nests (2004) (61)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (60)
The Genomic Landscape of Mucinous Breast Cancer. (2019) (60)
Genomic profiling of histological special types of breast cancer (2013) (59)
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB–NFIB fusion gene (2018) (58)
Delivering precision oncology to patients with cancer (2022) (57)
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2014) (57)
Distribution of p63, a novel myoepithelial marker, in fine‐needle aspiration biopsies of the breast (2003) (57)
Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. (2021) (57)
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (2019) (57)
Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers (2013) (56)
Are Triple-Negative and Basal-Like Breast Cancer Synonymous? (2008) (56)
Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy (2018) (55)
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022) (55)
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group (2020) (54)
Dysregulated TRK Signalling is a Therapeutic Target in CYLD Defective Tumours (2011) (53)
14-3-3σ stabilizes a complex of soluble actin and intermediate filament to enable breast tumor invasion (2013) (53)
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy (2006) (52)
The genetic landscape of breast carcinomas with neuroendocrine differentiation (2017) (52)
Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse. (2006) (52)
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. (2021) (51)
Transcriptome analysis of embryonic mammary cells reveals insights into mammary lineage establishment (2011) (51)
Targeting chromosomal instability and tumour heterogeneity in HER2‐positive breast cancer (2010) (51)
Non-operative breast pathology: columnar cell lesions (2006) (51)
Amplification and Overexpression of CACNA1E Correlates with Relapse in Favorable Histology Wilms' Tumors (2006) (51)
Next-generation sequencing applied to molecular diagnostics (2011) (51)
Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast (2017) (50)
Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast (2010) (50)
Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas. (2013) (50)
The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis‐generating study (2015) (49)
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. (2017) (49)
Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. (2018) (48)
Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma (2009) (48)
Maspin expression in normal skin and usual cutaneous carcinomas (2002) (48)
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. (2018) (47)
Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer? (2002) (47)
Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. (2019) (47)
Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis (2012) (46)
Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers (2014) (46)
Genetic Analysis of Microglandular Adenosis and Acinic Cell Carcinomas of the Breast Provides Evidence for the Existence of a Low-grade Triple-Negative Breast Neoplasia Family (2016) (46)
Congenital composite hemangioendothelioma: case report and reappraisal of the hemangioendothelioma spectrum (2002) (46)
Genomic profile of a secretory breast cancer with an ETV6–NTRK3 duplication (2009) (46)
Metastatic breast carcinomas display genomic and transcriptomic heterogeneity (2015) (45)
Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models (2014) (45)
Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation (2009) (45)
PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma (2014) (44)
Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer (2010) (44)
Intradermal spindle cell/pleomorphic lipoma of the vulva: case report and review of the literature (2002) (44)
Genetic characterization of breast cancer and implications for clinical management (2009) (43)
Genomic characterisation of acral melanoma cell lines (2012) (43)
Microglandular adenosis associated with triple‐negative breast cancer is a neoplastic lesion of triple‐negative phenotype harbouring TP53 somatic mutations (2016) (43)
Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast (2014) (43)
Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways (2017) (43)
Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort (2018) (42)
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. (2013) (42)
Bi‐allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer (2017) (42)
Invasive Breast Carcinoma: Introduction and general features (2012) (42)
Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box (2011) (42)
Impact of Basal-Like Breast Carcinoma Determination for a More Specific Therapy (2008) (42)
p63 staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast (2002) (41)
Triple-negative breast cancers — a panoply of cancer types (2018) (41)
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. (2012) (41)
Differential Prox-1 and CD 31 expression in mucousae, cutaneous and soft tissue vascular lesions and tumors. (2005) (41)
Sex differences in oncogenic mutational processes (2019) (41)
Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing (2014) (39)
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines (2011) (39)
Molecular Alterations of KIT Oncogene in Gliomas (2007) (39)
Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships (2016) (38)
Multifaceted Dysregulation of the Epidermal Growth Factor Receptor Pathway in Clear Cell Sarcoma of the Kidney (2007) (37)
Taxane benefit in breast cancer—a role for grade and chromosomal stability (2013) (37)
AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients (2016) (37)
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. (2014) (37)
Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential (2019) (37)
Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype‐matched ductal and lobular carcinomas (2010) (37)
Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas (2008) (37)
Synthetic Lethality in Cancer Therapeutics: The Next Generation. (2021) (37)
Translating neoadjuvant therapy into survival benefits: one size does not fit all (2016) (37)
Genome‐wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c‐Kit, CD117) and oestrogen receptor‐α (ERα) in response to therapeutic radiation (2009) (37)
Influence of whole arm loss of chromosome 16q on gene expression patterns in oestrogen receptor‐positive, invasive breast cancer (2011) (36)
Genomic profile of advanced breast cancer in circulating tumour DNA (2021) (36)
Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations (2013) (35)
Non-operative breast pathology: lobular neoplasia (2006) (35)
Functional characterization of EMSY gene amplification in human cancers (2011) (35)
Composite cervical adenocarcinoma composed of adenoma malignum and gastric type adenocarcinoma (dedifferentiated adenoma malignum) in a patient with Peutz Jeghers syndrome (2010) (35)
Infiltrating S100A8+ myeloid cells promote metastatic spread of human breast cancer and predict poor clinical outcome (2014) (35)
Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma (2018) (34)
Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (34)
Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. (2016) (34)
Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management (2016) (34)
Mammary Epithelioid Myofibroblastoma Arising in Bilateral Gynecomastia (2001) (34)
P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. (2002) (33)
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (2019) (33)
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer (2019) (33)
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative (2021) (33)
Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study (2010) (32)
Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases (2021) (32)
Evaluation of cell proliferation, epidermal growth factor receptor, and bcl‐2 immunoexpression as prognostic factors for patients with world health organization grade 2 oligodendroglioma (2000) (32)
Primary epithelial malignant mesothelioma of the pericardium with deciduoid features: Cytohistologic and immunohistochemical study (2002) (32)
Lobular in situ neoplasia and columnar cell lesions: diagnosis in breast core biopsies and implications for management (2007) (32)
Phenotype-Genotype Correlation in Familial Breast Cancer (2011) (32)
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases (2018) (32)
Contralateral breast cancers: Independent cancers or metastases? (2018) (32)
Clinicopathologic implications of E‐cadherin reactivity in patients with lobular carcinoma in situ of the breast (2002) (31)
Eosinophilic angiocentric fibrosis of the sinonasal tract: Report on the clinicopathologic features of a case and review of the literature (2002) (31)
Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion (2015) (31)
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. (2020) (30)
Cytokeratin 5/6 in normal human breast: lack of evidence for a stem cell phenotype (2004) (30)
Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells (2006) (30)
Independent real‐world application of a clinical‐grade automated prostate cancer detection system (2021) (30)
Are acinic cell carcinomas of the breast and salivary glands distinct diseases? (2015) (30)
Metastatic breast carcinomas display genomic and transcriptomic heterogeneity (2015) (30)
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer (2022) (29)
Hypoxia can be detected in irradiated normal human tissue: a study using the hypoxic marker pimonidazole hydrochloride. (2007) (29)
Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer (2010) (29)
c-KIT overexpression, without gene amplification and mutation, in paediatric renal tumours (2007) (29)
DICER1 hotspot mutations in non-epithelial gonadal tumours (2013) (29)
Activating mutations in HER2: neu opportunities and neu challenges. (2013) (28)
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies (2014) (28)
Pathogenesis of Triple-Negative Breast Cancer. (2022) (28)
Beyond triple-negative breast cancer: the need to define new subtypes (2010) (28)
Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor (2016) (27)
Perilobar Nephrogenic Rests Are Nonobligate Molecular Genetic Precursor Lesions of Insulin-Like Growth Factor-II-Associated Wilms Tumors (2008) (27)
Implications of rarity of chromosome 17 polysomy in breast cancer. (2011) (27)
Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. (2020) (27)
Genomic profiling of primary and recurrent adult granulosa cell tumors of the ovary (2020) (27)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer (2020) (27)
The molecular genetic make-up of male breast cancer. (2019) (27)
The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. (2019) (27)
Direct evidence for concurrent morphological and genetic heterogeneity in an invasive ductal carcinoma of triple-negative phenotype (2011) (26)
Oncocytic carcinoma of the breast: frequency, morphology and follow-up. (2011) (26)
Sarcomatoid variant of anaplastic large cell lymphoma mimicking a primary breast cancer: a challenging diagnosis. (2002) (26)
Primary fibromatosis of the breast in a patient with multiple desmoid tumors--report of a case with evaluation of estrogen and progesterone receptors. (2001) (26)
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy (2019) (25)
Classic Kaposi's sarcoma of the tongue: case report with emphasis on the differential diagnosis. (2002) (25)
Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure (2015) (25)
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. (2010) (24)
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (24)
INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors (2021) (24)
Epistatic interactions and drug response (2014) (24)
Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma (2020) (24)
Somatic mutations in leukocytes infiltrating primary breast cancers (2015) (23)
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations. (2012) (23)
Lack of PRKD2 and PRKD3 kinase domain somatic mutations in PRKD1 wild‐type classic polymorphous low‐grade adenocarcinomas of the salivary gland (2016) (23)
BRCA1 and stem cells: tumour typecasting (2008) (23)
Where Birt–Hogg–Dubé meets Cowden Syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours (2013) (23)
Generation of conditional oncogenic chromosomal translocations using CRISPR–Cas9 genomic editing and homology‐directed repair (2017) (23)
Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile (2016) (23)
DNA amplifications in breast cancer: genotypic-phenotypic correlations. (2010) (22)
P63-driven nuclear accumulation of beta-catenin is not a frequent event in human neoplasms. (2003) (22)
ESR1 gene amplification in breast cancer: a common phenomenon? (2008) (22)
Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: Implications for interpretation of liquid biopsy tests. (2017) (22)
Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary (2020) (22)
Immunohistochemical Analysis of IDH2 R172 Hotspot Mutations in Breast Papillary Neoplasms: Applications in the Diagnosis of Tall Cell Carcinoma with Reverse Polarity (2019) (22)
Naked nuclei revisited: p63 Immunoexpression (2002) (22)
Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing (2016) (22)
Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers (2019) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Maspin is expressed in the nuclei of breast myoepithelial cells (2002) (21)
Endometrial Cancers in BRCA1 or BRCA2 Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. (2019) (21)
Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG) (2020) (21)
High-throughput detection of fusion genes in cancer using the Sequenom MassARRAY platform (2011) (21)
Vascular endothelial growth factor, transforming growth factor-alpha, and estrogen receptors: possible cross-talks and interactions. (2002) (21)
Non-existence of caveolin-1 gene mutations in human breast cancer (2011) (20)
Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis‐generating study (2017) (20)
Pediatric pigmented dermatofibrosarcoma protuberans (Bednár tumor): case report and review of the literature with emphasis on the differential diagnosis. (2002) (20)
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway (2021) (20)
Angiogenesis in lymph node metastases (2002) (20)
Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas (2019) (20)
August 2003: 47‐year‐old female with a 7‐year history of osteomalacia and hypophosphatemia (2004) (20)
DNA Copy Number Aberrations, and Human Papillomavirus Status in Penile Carcinoma. Clinico-Pathological Correlations and Potential Driver Genes (2016) (20)
V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer. (2019) (20)
Amphicrine gastric carcinoma. (2001) (20)
Absence of microsatellite instability in mucinous carcinomas of the breast. (2010) (20)
PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid (2019) (20)
Problematic breast tumors reassessed in light of novel molecular data (2020) (19)
A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability. (2020) (19)
Determining PD-L1 Status in Patients with Triple-Negative Breast Cancer: Lessons Learned from IMpassion130. (2021) (19)
Lobular in situ neoplasia (2004) (19)
Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma (2020) (19)
Bilateral gonadoblastomas in a dog with mixed gonadal dysgenesis. (2004) (19)
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma (2021) (19)
Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer (2008) (19)
Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer (2017) (19)
Fluorescence in situ hybridization, comparative genomic hybridization, and other molecular biology techniques in the analysis of effusions (2005) (18)
Molecular diagnosis in breast cancer (2008) (18)
Differential Ki67 and bcl‐2 immunoexpression in solid–glandular and spindle cell components of biphasic synovial sarcoma: a double immunostaining assessment with cytokeratin and vimentin (2002) (18)
Comparative Genomic Hybridisation Arrays: High-Throughput Tools to Determine Targeted Therapy in Breast Cancer (2008) (18)
Collagenous spherulosis in an adenomyoepithelioma of the breast (2003) (18)
Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology (2012) (18)
Microglandular adenosis: a non-obligate precursor of triple-negative breast cancer? (2013) (18)
Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer. (2015) (18)
Histologic Spectrum of Polymorphous Adenocarcinoma of the Salivary Gland Harbor Genetic Alterations Affecting PRKD Genes (2019) (18)
Invasion in breast lesions: the role of the epithelial–stroma barrier (2018) (18)
Genome-wide expression profiling as a clinical tool (2009) (18)
Ultraviolet radiation drives mutations in a subset of mucosal melanomas (2021) (17)
An introduction to genes, genomes and disease (2010) (17)
Breast pathology: beyond morphology. (2010) (17)
BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer. (2020) (17)
Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping (2012) (16)
The genomic landscape of metastatic histologic special types of invasive breast cancer (2020) (16)
Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas (2019) (16)
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma (2019) (15)
Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. (2014) (15)
PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. (2015) (15)
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer (2021) (15)
Radiogenomics Analysis of Intratumor Heterogeneity in a Patient With High-Grade Serous Ovarian Cancer. (2019) (15)
Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults (2018) (15)
Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping. (2012) (15)
Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance (2014) (15)
The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas (2020) (15)
Abstract 5277: The cBioPortal for cancer genomics and its application in precision oncology (2016) (14)
Glassy Cell Carcinoma of the Uterine Cervix (2001) (14)
Pseudoepitheliomatous hyperplasia in cutaneous malignant melanoma: a rare and misleading feature. (2001) (14)
The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers (2019) (14)
Novel patterns of complex structural variation revealed across thousands of cancer genome graphs (2019) (14)
Whole‐exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast (2019) (14)
Molecular profiling of ER+ metastatic breast cancers to reveal association of genomic alterations with acquired resistance to CDK4/6 inhibitors. (2019) (14)
Mutant SF3B1 promotes AKT and NF-kB driven mammary tumorigenesis. (2020) (13)
Diverse BRCA 1 and BRCA 2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer (2017) (13)
Epithelioid malignant peripheral nerve sheath tumour: case report and review of the previously published cases (2002) (13)
Caveolin-1 P132L mutation in human cancers: 1 CAVeat to be voiced. (2010) (13)
Enhanced RAD21 Cohesin Expression Confers Poor Prognosis and Resistance to Chemotherapy in High Grade Luminal, Basal, and HER 2 Breast Cancers (2014) (13)
Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway (2019) (13)
P‐cadherin expression in canine lactating mammary gland (2002) (13)
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. (2021) (12)
April 2001: a 70 year old woman with recurrent meningioma. (2001) (12)
The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features (2021) (12)
Malignant peripheral nerve sheath tumour-like primary cutaneous malignant melanoma (2004) (12)
Pathology in drug discovery and development (2014) (12)
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer (2016) (12)
Identification of NTN 4 , TRA 1 , and STC 2 as Prognostic Markers in Breast Cancer ina Screenfor Signal Sequence EncodingProteins (2007) (12)
Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications (2017) (11)
Cavernous sinus thrombosis caused by zygomycosis after unrelated bone marrow transplantation (2001) (11)
Pathologic quiz case: a 62-year-old woman with a 4.5-cm nodule in the right breast. Lipid-rich breast carcinoma. (2003) (11)
Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes (2020) (11)
Pathologic Quiz Case: A 93-Year-Old Woman With an Enlarged and Tender Left Breast (2003) (11)
Development of therapeutic approaches to 'triple negative' phenotype breast cancer. (2008) (10)
Massively parallel sequencing analysis of benign melanocytic naevi (2019) (10)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (10)
Pathologic Quiz Case: A 36-Year-Old Woman With Muscle Pain and Weakness (2002) (10)
Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes (2020) (10)
CAV1 and CAV2 are associated with breast cancer basal-like and triple negative immunophenotype (2008) (10)
Hyaline cell-rich chondroid syringoma: case report and review of the literature. (2002) (10)
Primary cutaneous malignant melanoma with lipoblast-like cells. (2003) (9)
Pathologic quiz case. A 36-year-old woman with muscle pain and weakness. Phosphaturic mesenchymal tumor (mixed connective tissue variant)/oncogenic osteomalacia. (2002) (9)
Cancer Causative Mutations Occurring in Early Embryogenesis. (2021) (9)
High-resolution genomic profiling of thyroid lesions uncovers preferential copy number gains affecting mitochondrial biogenesis loci in the oncocytic variants. (2015) (9)
Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors (2021) (9)
Molecular Classification of Breast Cancer. (2012) (9)
Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management (2020) (9)
Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. (2021) (9)
Re: Korsching et al. The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005; 206: 451–457 (2005) (9)
Tumor and Stem Cell Biology Cancer Research FGFR 1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer (2010) (9)
Transcriptional upregulation and unmethylation of the promoter region of p16 in invasive basal cell carcinoma cells and partial co‐localization with the γ2 chain of laminin‐332 (2007) (9)
Giant cell collagenoma: case report and review of the literature (2002) (8)
Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer. (2017) (8)
Single-cell genomic variation induced by mutational processes in cancer (2022) (8)
CASES OF THE MONTH: April 2001 – June 2001 (2001) (8)
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer (2015) (8)
Oncogenic properties and signaling basis of the PAX8‐GLIS3 fusion gene (2020) (8)
Expression of Hepatocyte Growth Factor and Its Receptor Met in Wilms' Tumors and Nephrogenic Rests Reflects Their Roles in Kidney Development (2009) (8)
Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours (2007) (8)
Evaluating clonal hematopoiesis in tumor infiltrating leukocytes in breast cancer and secondary hematologic malignancies. (2019) (8)
Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast (2017) (8)
c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant? (2003) (7)
Abstract 8: Genomic analyses of heterogeneous HER2 3+ invasive ductal carcinomas of the breast (2012) (7)
Homologous recombination deficiency: how genomic signatures are generated. (2021) (7)
SCLEROSING EPITHELIOID MESENCHYMAL NEOPLASM OF THE PANCREAS A PROPOSED NEW ENTITY (2019) (7)
The Birth of an Adenoid Cystic Carcinoma (2015) (7)
Oncogenes, granules and breast cancer: what has c-myc to do with apocrine changes? (2002) (7)
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. (2016) (7)
The genomic landscape of carcinomas with mucinous differentiation (2021) (7)
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling (2020) (7)
Microarray‐Based Comparative Genomic Hybridization (2009) (7)
Genomic characterization of small cell carcinomas of the uterine cervix (2021) (7)
Pathologic quiz case: a 93-year-old woman with an enlarged and tender left breast. Histiocytoid variant of lobular breast carcinoma. (2003) (6)
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer (2021) (6)
Lobular Neoplasia and Invasive Lobular Carcinoma (2012) (6)
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. (2021) (6)
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development (2021) (6)
(V600E)Braf::Tyr-CreERT2::K14-Kitl mice do not develop superficial spreading-like melanoma: keratinocyte Kit ligand is insufficient to "translocate" (V600E)Braf-driven melanoma to the epidermis. (2012) (6)
Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes (2020) (6)
Glassy cell carcinoma of the uterine cervix. Report of a case with cytohistologic and immunohistochemical study. (2001) (6)
Genomic analysis of recurrences and high‐grade forms of polymorphous adenocarcinoma (2019) (6)
Gastrointestinal tumors, non-colorectal (2012) (6)
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials (2020) (6)
ESR1 and endocrine therapy resistance: more than just mutations. (2018) (6)
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing (2022) (6)
Abstract CT030: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial (2022) (5)
The Molecular Evolution of Breast Cancer Precursors and Risk Indicators (2011) (5)
Pathology and Molecular Pathology of Breast Cancer (2017) (5)
The impact of mutational processes on structural genomic plasticity in cancer cells (2021) (5)
Immunohistochemistry and Molecular Biology of Breast Cancers: Old and New Prognostic Factors (2011) (5)
Ki67 Assessment in Breast Cancer: Are We There yet? (2020) (5)
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. (2014) (5)
Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype? (2017) (5)
Prediction of Trastuzumab Benefit in HER2-Positive Breast Cancers: Is It in the Intrinsic Subtype? (2017) (5)
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification (2015) (5)
[Primary pediatric tumours of the central nervous system. Anatomopathological study of 623 cases]. (1997) (5)
Whole‐exome analysis of metaplastic breast carcinomas with extensive osseous differentiation (2020) (5)
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. (2022) (5)
Anti-HER2 therapies: when more is more (2012) (4)
Rectal leiomyosarcoma mna dog and review of gastrointestinal stromal tumours (2003) (4)
Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors (2021) (4)
Prognostic signatures in breast cancer: correlation does not imply causation (2012) (4)
Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies (2019) (4)
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome (2021) (4)
Lipoma-like hibernoma: an atypical lipoma/well-differentiated liposarcoma mimicker (2002) (4)
Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. (2021) (4)
Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. (2022) (4)
MSK-ACCESS for noninvasive somatic mutation profiling of lung cancers utilizing circulating tumor DNA. (2020) (4)
Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. (2021) (4)
Back to the basis: breast cancer heterogeneity from an etiological perspective. (2014) (4)
Columnar cell lesions of the breast (2005) (4)
From Expression Profiling to Routine Practice (2009) (4)
Fine needle aspiration cytology of paratesticular rhabdomyosarcoma mimicking a testicular germ cell tumor. (2002) (4)
Abstract GS2-01: High levels of interferon-response gene signatures are associated withde novoand acquired resistance to CDK4/6 inhibitors in ER+ breast cancer (2020) (4)
Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). (2008) (4)
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies (2021) (4)
Abstract GS4-08: Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance (2022) (4)
[Genome-wide expression profiling as a clinical tool: are we there yet?]. (2009) (3)
Pathologic quiz case: a 53-year-old man with a slowly enlarging mass in the right leg. (2009) (3)
A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC). (2020) (3)
Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas. (2010) (3)
[Krabbe s disease - case report] (2000) (3)
Abstract PD4-13: Estrogen receptor-negative breast adenomyoepitheliomas are driven by co-occurring HRAS hotspot and PI3K pathway gene mutations: A genetic and functional analysis (2018) (3)
Abstract 927: Targeted capture next generation sequencing of fresh frozen lobular carcinoma in situ and invasive lobular cancer identifies a common repertoire of mutations (2014) (3)
Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Potential Therapeutic Targets Including Amplifications of FGFR2. (2009) (3)
Circulating Tumor DNA as a Biomarker in Oligometastatic Non-small Cell Lung Cancer (2020) (3)
Ancillary Studies for Salivary Gland Cytology (2018) (3)
Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer. (2009) (3)
Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients (2022) (3)
Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites (2020) (3)
Pathogenic Mutations in ATM As Determinants of Local Control in Non-Small Cell Lung Cancers Treated with Radiation Therapy (2018) (3)
Bcl2 as a surrogate prognostic and predictive marker in triple-negative breast cancer. (2011) (3)
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination (2021) (3)
Lobular Carcinoma In Situ: Biology and Pathology (2004) (3)
Abstract S4-03: A functional assay for homologous recombination (HR) DNA repair and whole exome sequencing reveal that HR-defective sporadic breast cancers are enriched for genetic alterations in DNA repair genes (2016) (3)
Abstract PD6-5: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data (2013) (3)
Reply to Rosen (2017) (2)
Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma (2017) (2)
Molecular genetics of ADH/DCIS and ALH/LCIS (2006) (2)
Abstract 2547: Discovery and characterization of late-stage breast cancer estrogen receptor alpha 1 bound long non-coding RNAs (2017) (2)
Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. (2022) (2)
MOLECULAR OF BREAST CANCER (2012) (2)
Abstract 2138: Functional characterization of the 19q12 amplicon in grade 3 breast cancers (2010) (2)
Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma (2021) (2)
Stromal MED12 exon 2 mutations in complex fibroadenomas of the breast (2020) (2)
Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study (2021) (2)
PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays (2021) (2)
Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer. (2022) (2)
Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes (2021) (2)
PG 2.03 Discrepancies between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa (2015) (2)
Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers (2013) (2)
Abstract S6-06: High-depth massively parallel sequencing reveals heterogeneity between primary tumor and metastatic deposits in de novo metastatic breast cancer patients prior to exposure to systemic therapy (2013) (2)
Pathogenic Mutations in ATM Predict for Enhanced Local Control in Prostate Cancers Treated with Radiation Thearpy (2018) (2)
Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression (2022) (2)
Independent validation of paige prostate: Assessing clinical benefit of an artificial intelligence tool within a digital diagnostic pathology laboratory workflow. (2020) (2)
Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer (2022) (2)
Cancer Therapy : Preclinical PI 3 K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines (2013) (2)
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers (2022) (2)
Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy in breast cancer. (2010) (2)
210O Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC) (2022) (2)
Abstract S6-06: The genomic landscape of male breast cancers (2015) (2)
Expanded genetic testing of GIST patients identifies high proportion of non-syndromic patients with germline alterations (2023) (2)
Markers for Breast Cancer Myoepithelial Breast Cells : Identification of Novel Prognostic Expression Profiling of Purified Normal Human Luminal and Updated (2004) (2)
Genomic determinants of early recurrences in low-stage low-grade endometrioid endometrial carcinoma. (2022) (1)
Circulating tumor DNA (ctDNA) determinants of improved outcomes in patients (pts) with advanced solid tumors receiving the ataxia telangiectasia and Rad3-related inhibitor (ATRi), RP-3500, in the phase 1/2a TRESR trial (NCT04497116). (2022) (1)
O-80 CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome (2007) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Pleomorphic lobular carcinoma in situ (2013) (1)
Functional characterization of the 19q12 amplicon in grade III breast cancers (2012) (1)
Abstract PD3-4: Reliability of whole exome sequencing for assessing intratumor heterogeneity from breast tumor biopsies (2015) (1)
Abstract S4-02: Integrated genomic analyses of members of protein kinase C family identifies subtype specific alterations as novel therapeutic targets (2013) (1)
Pathogenic Mutations in ATM Enhance Radio-Sensitivity and Local Control in Patients with Primary and Metastatic Breast Cancer (2018) (1)
Triple negative and basal-like breast cancer : one or many diseases ? Implications for surgical pathologists (2009) (1)
Letter Are triple-negative tumours and basal-like breast cancer (2007) (1)
Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines (2009) (1)
Human Cancer Biology PI 3 K Pathway Activation in High-Grade Ductal Carcinoma In Situ — Implications for Progression to Invasive Breast Carcinoma (2014) (1)
Abstract 949: ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer (2019) (1)
Homologous recombination DNA repair defects in copy-number high serous-like endometrial cancers (2019) (1)
Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations (2014) (1)
Abstract A2-02: SF3B1 mutations constitute a novel therapeutic target in breast cancer (2015) (1)
Reactive spindle cell nodules of the breast. (2001) (1)
Bcl2 expression and prediction of outcomes to anthracycline-based neoadjuvant chemotherapy in ER-positive breast cancer and to nonanthracycline adjuvant therapy. (2011) (1)
Breast cancer intra-tumor heterogeneity (2014) (1)
Ewing's sarcoma of the rectum: can we afford not to use molecular pathology? (2005) (1)
Blastemal/stromal expression of IGF1R in Wilms tumours is driven by increased copy number and correlates with relapse (2006) (1)
Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (1)
Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast (2017) (1)
Whole‐exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma (2020) (1)
Triple-Negative and Basal-like Carcinoma (2012) (1)
A Randomised Multicentre Trial of Epirubicin, Oxaliplatin and Capecitabine (EOC) + Panitumumab in advanced Oesophago-Gastric Cancer (REAL3): Updated Results (2012) (1)
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (1)
Lobular Carcinoma In Situ : Biology and Management (2013) (1)
Combining two antibodies to define E‐cadherin loss of expression in non‐lobular breast carcinomas: when less is more (2013) (1)
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants (2019) (1)
The importance of gene-centring microarray data – Authors' reply (2010) (1)
Patient-derived xenograft (PDX) models in basic and translational breast cancer research (2016) (1)
An Investigation into a Panel of Isogenic Taxane Resistant Breast Cancer Cell Lines Using Transcriptomic and Genomic Methods. (2009) (1)
Abstract P2-13-19: Statin modulation of antibody drug conjugate activity in breast cancer models and patients (2022) (1)
Preclinical evaluation of the PARP-inhibitor olaparib for the treatment of ovarian clear cell cancer (2011) (1)
Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance (2014) (1)
Abstract P3-06-08: Mucinous and neuroendocrine breast cancers: A spectrum of genetically-related lesions distinct from common forms of estrogen receptor-positive breast cancers (2019) (1)
Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix (2022) (1)
Molecular diagnostics: the key driver in personalized cancer medicine, Jan T Jorgensen, Henrik Winther (Eds.). Pan Stanford Publishing (2010), Pp 300, £121.95., ISBN: 978-9814241441 (2010) (1)
Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications (2022) (1)
LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer (2022) (1)
Abstract S2-02: The landscape of somatic genetic alterations in BRCA1 and BRCA2 breast cancers (2016) (1)
Cutaneous Malignant Melanoma: The Great Simulator (2003) (1)
Invasive micropapillary breast cancer: Single-institution experience in the modern era. (2013) (1)
Abstract P1-07-06: Immune signatures define and affect prognosis in triple-negative breast cancer subtypes (2017) (1)
Acquisition of APOBEC Mutagenesis and Microsatellite Instability Signatures in the Development of Brain Metastases in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. (2020) (1)
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers (2016) (1)
Abstract 4167: Ultraviolet radiation cooperates with individual oncogenes to drive melanomagenesis through distinct molecular mechanisms (2016) (1)
Rare Breast Carcinomas (2012) (1)
Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers (2022) (1)
Pathologic quiz case. Multicystic ovarian tumor in a 46-year-old female patient. (2009) (1)
Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers (2022) (1)
Predictive Biomarkers and Personalized Medicine A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (1)
Abstract 1787: Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer (2022) (1)
Prognostic signatures in breast cancer: correlation does not imply causation (2012) (1)
A New Pathological Response Index (PRI) for Neoadjuvant Chemotherapy Accurately Predicts Clinical Outcomes of Locally Advanced Primary Breast Cancers (LAPBC) (2011) (1)
Early ctDNA response assessment for prediction of platinum sensitivity in small cell lung cancer. (2020) (1)
Abstract P4-05-08: Genomic landscape of breast cancer occurring in elderly individuals (2020) (1)
Abstract 2989: Intra-tumor heterogeneity and clonal changes in the progression of DCIS to invasiveness: Combined tumor bulk and single cell analysis (2015) (1)
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy (2022) (1)
Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma (2021) (1)
99P Analysis of ctDNA in advanced breast cancer reveals polyclonal disease associated with adverse outcome (2021) (1)
Topoisomerase 2 alpha as a predictor of response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer (2010) (1)
5015 The need for a biological grading system and its relationship to the current Nottingham histological grading system (NGS) (2009) (1)
Granular cell tumor of thyroid: a case series with molecular characterization highlighting unique pitfalls (2022) (1)
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance (2021) (1)
Abstract PD05-08: Genomic characterisation of invasive breast cancers with heterogeneous HER2 gene amplification (2012) (1)
Genomic Applications in Breast Carcinoma (2018) (1)
Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles. (2022) (1)
A 62-year-old woman with a 4.5-cm nodule in the right breast (2003) (1)
Hemangioendothelioma Identification of a Disease-Defining Gene Fusion in Epithelioid (2011) (1)
Pilot trial of an implantable microdevice for In Vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy. (2016) (1)
Clinical Validation of Artificial Intelligence-Augmented Pathology Diagnosis Demonstrates Significant Gains in Diagnostic Accuracy in Prostate Cancer Detection. (2022) (1)
[Neurocutaneous melanosis] (1999) (1)
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer (2021) (1)
Abstract P6-03-10: Genomic and transcriptomic heterogeneity in metaplastic breast carcinomas (2016) (1)
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance (2022) (1)
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group (2021) (1)
Abstract 930: Analysis of cell-free tumor DNA in cerebrospinal fluid to characterize and monitor the genetic alterations of brain tumors (2015) (1)
Abstract P4-02-03: Gene Copy Number Alterations Related to mRNA and miRNA Expression in Endocrine Resistant Breast Cancers (2010) (0)
Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA (2021) (0)
Breast cancer phenotype and genetic alterations: how are they connected? (2008) (0)
Abstract P4-02-01: High-depth sequencing of circulating tumor DNA to interrogate the genetics of residual micro-metastatic disease prior to relapse in early breast cancer (2015) (0)
LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer (2022) (0)
A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations (2010) (0)
The molecular pathology of ER, PR HER2 negative breast cancers: finding novel biomarkers (2008) (0)
P PROGNOSIS IMPACT OF POSTOPERATIVE RADIATION IN PATIENTS WITH RADICAL ESOPHAGECTOMY AND PATHOLOGIC LYMPH NODES POSITIVE ESOPHAGEAL CANCER (2012) (0)
Abstract P4-02-18: Impact of clonal hematopoiesis on disease progression following CDK4/6 inhibitor therapy (2023) (0)
Abstract P2-04-16: CD103+/PD-1+ T-cells identify a subset of triple-negative breast cancer eligible for targeted checkpoint inhibition (2017) (0)
Abstract 3376: Early onset of chromosomal instability in breast preneoplasia detected by single-cell genomics (2018) (0)
[Cerebrovascular diseases in patients aged 15 to 40 years: neuropathological findings in 47 cases]. (2001) (0)
Abstract P2-01-02: Whole exome sequencing analysis of the progression from ductal carcinomain situto invasive ductal carcinoma (2019) (0)
Abstract 4509: Clinical genomic profiling of 1000 metastatic breast cancer patients: actionable targets, novel alterations, and clinical correlations (2016) (0)
Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363). (2016) (0)
Abstract 91: The mutational landscape of mucinous carcinomas of the breast (2016) (0)
Abstract P2-06-04: Pathognomonic long molecule footprints of backup repair pathways in homologous recombination deficient cancers (2022) (0)
Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas (2021) (0)
Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer (2022) (0)
Abstract P1-06-08: A p53-independent DNA damage response that regulates breast cancer phenotypes (2019) (0)
Primary salivary clear cell tumors. (2003) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
5175 Columnar cell lesions are the early precursors of some forms of invasive breast carcinoma – a new genetic map for the evolutionary pathway of low nuclear grade breast neoplasia (LNGBN) family (2009) (0)
229 Genetic heterogeneity of ovarian sex cord-stromal tumors (2019) (0)
Issue Information (2018) (0)
Abstract 1544: The clinical behavior of endometrioid and serous endometrial carcinomas is governed by distinct biological processes (2014) (0)
Molecular alterations of PDGA and PDGFRA in Gliomas (2009) (0)
Abstract 4829: Massively parallel RNA sequencing analysis of micropapillary carcinomas of the breast (2011) (0)
Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation study (2023) (0)
Impact of clonal hematopoiesis on tumor control following radiation therapy. (2022) (0)
Abstract 4284: Enhancing subclonal reconstruction algorithm for resolving complex tumor phylogenies from multi-sample tumor DNA sequencing (2023) (0)
Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors (2021) (0)
86 Molecular Diagnostics in Breast Cancer – Getting Beyond ER, PR, HER2 and Proliferation (2012) (0)
Abstract P4-05-07: Whole-exome and RNA-sequencing analyses of acinic cell carcinomas of the breast (2020) (0)
Short communication Next-generation sequencing (0)
Abstract P2-23-15: Histologic, immunohistochemical and genomic comparison between classic Invasive lobular carcinomas and lobular-like invasive ductal carcinomas (2023) (0)
Abstract P3-04-07: Functional BRCA-pathway defects in sporadic breast cancers rarely show a significant reduction in BRCA-pathway proteins (2013) (0)
Abstract 4835: Genetic determinants of mTOR inhibitor response in breast and endometrial cancer (2012) (0)
P43: Genomic changes in favourable histology Wilms tumours analysed by genome-wide 1 Mb-spaced and chromosome 1 tiling-path array CGH (2005) (0)
Abstract P4-05-01: Massively parallel sequencing analysis of microsatellite instability in breast cancer (2020) (0)
Abstract 2132: Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression (2023) (0)
Running title : CTCs and staging in MBC (2018) (0)
Molecular investigation of breast cancer (2013) (0)
5174 POSTER Topoisomerase ∥α (TOPO2A) Protein Overexpression Predicts Response to Anthracycline-based Chemotherapy Irrespective of HER2 Status (2011) (0)
Abstract P4-02-01: Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer (2023) (0)
Special Topics on Bioinformatics: Intro to Biomolecular Structures and Genetics (2010) (0)
Abstract PD4-07: PD4-07 Uncovering molecular heterogeneity of mixed ductal and lobular carcinoma using digital spatial profiling (2023) (0)
575 SF3B1 mutations are associated with alternative splicing in ER-positive breast cancer (2014) (0)
Male breast cancer : genomic profiling 1 The Genomic Landscape of Male Breast Cancers (2016) (0)
Expression of HGF and it’s receptor MET in Wilms tumours and nephrohgenic rests (2007) (0)
Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer (2020) (0)
Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin-embedded tumor samples using a novel tumor-only sequencing panel. (2023) (0)
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas (2018) (0)
Re: Sastre‐Garau et al. Inflammatory myofibroblastic tumour (inflammatory pseudotumour) of the breast: clinicopathological and genetic analysis of a case with evidence for clonality. J Pathol 2002; 196: 97–102 (2003) (0)
Abstract P2-05-08: Mucinous breast carcinomas: A genomically distinct subtype of estrogen receptor-positive invasive breast cancers (2018) (0)
431 Distant metastatic spread and clonal evolution of high-grade endometrial cancers (2020) (0)
Abstract PD1-06: Apobec mutagenesis is a pervasive feature of poor prognosis breast cancer associating with ESR1 wild type, endocrine resistant disease (2022) (0)
Analysis of 134 formalin-fixed paraffin-em bedded synovial sarcomas by conventional RT-PCR, real time RT-PCR and dual colour FISH (2007) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
Landscape of somatic genetic alterations in endometrioid endometrial cancers with germline and somatic PTEN mutations (2018) (0)
The genomic profiling of penile carcinoma: DNA copy number aberrations and validation of candidate driver genes (2017) (0)
Abstract P4-17-01: Genomic profiling of primary and metastatic breast cancer in men (2020) (0)
Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development (2021) (0)
Abstract P1-05-03: The genomic landscape of breast metaplastic carcinoma (2017) (0)
Letter to the Editor (2008) (0)
Abstract PD4-5: Longitudinal massively parallel sequencing analysis of circulating cell-free tumor DNA: A feasibility study (2013) (0)
Identifying somatic oncogenic mutations in leukocytes that infiltrate primary breast cancers. (2015) (0)
Abstract PD11-01: An artificial intelligence-based predictor of CDH1 biallelic mutations and invasive lobular carcinoma (2022) (0)
Ultraviolet radiation drives mutations in a subset of mucosal melanomas (2021) (0)
Molecular characterisation of cell line models for triple-negative breast cancers (2012) (0)
Abstract P3-06-09: Test of association between Ki67 index of early breast cancer and local relapse after adjuvant hypofractionated radiotherapy. (2012) (0)
Abstract P4-05-10: PIK3CA mutations are enriched in invasive lobular carcinomas and invasive mammary carcinomas with lobular features: Results from a TCGA sub-analysis (2013) (0)
KIT genetic alterations in breast cancer (2022) (0)
Abstract 5721: Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival (2023) (0)
Abstract PD6-02: Digital MammaPrint and BluePrint using machine learning and whole slide imaging (2021) (0)
Abstract P2-05-03: Novel driver genetic alterations in MYB-NFIB-negative breast adenoid cystic carcinomas (2018) (0)
O-39 Morphological and molecular evolutionary pathways of low and high grade breast cancers and theier putative precursor lesions (2007) (0)
Diagnostic yield and clinical relevance of expanded genetic testing for cancer patients (2022) (0)
How should we best target the biology of ER PR HER2 negative breast cancer (2008) (0)
Abstract 6063: Genomic characterization of non-small cell lung cancer (NSCLC) brain metastasis (BM) patients identifies novel alterations associated with tropisms and disease progression (2023) (0)
Abstract 138: Solid papillary carcinoma with reverse polarization are driven by IDH2 and PI3K pathway mutations (2016) (0)
Hyperplastic/proliferating perilobar nephrogenic rests are molecular genetic precursor lesions of Wilms tumor (2007) (0)
Mutation detection in cell-free DNA using ultra-high depth sequencing in prospectively collected newly diagnosed endometrial cancer patients (2020) (0)
Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non–small cell lung cancer (NSCLC) treated with definitive radiation therapy. (2022) (0)
Abstract PD14-03: Genetic and epigenetic basis of invasive lobular carcinomas lacking CDH1-alterations (2022) (0)
Abstract PR05: The effect of chemotherapy on HER2+ breast cancer heterogeneity measured by STAR-FISH: Detection of PIK3CA mutation and HER2 amplification at single-cell level in situ (2016) (0)
Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas (2023) (0)
Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers. (2022) (0)
Abstract 709: The utility of plasma ctDNA for detection ofKRASG12C and other mutations in lung cancers (2020) (0)
902 ORAL Expression of KIT (c-Kit; CD117) is reduced after radiation in normal human breast tissue: a study using cDNA array analysis of microdissected samples (2007) (0)
TERT Hotspot Promoter Mutations and TERT Gene Amplification in Phyllodes Tumors of the Breast (2016) (0)
Abstract 3889: Genetic heterogeneity and distinct driver mutations in synchronous primary and metastatic breast cancers from therapy-naïve patients (2015) (0)
Abstract P1-05-04: Intra-tumor genetic heterogeneity and histologic heterogeneity within metaplastic breast cancers: Genotypic-phenotypic correlations (2017) (0)
Abstract A21: Modeling of oncogenic chromosomal translocations of aggressive fusion-positive sarcomas by CRISPR-Cas9 genomic engineering (2018) (0)
CDK12 loss leads to replication stress and sensitivity to combinations of the ATR inhibitor camonsertib (RP-3500) with PARP inhibitors (2022) (0)
Abstract 4472: PI3K pathway dependencies in endometrioid endometrial cancer. (2013) (0)
Abstract P4-05-11: Methylation profiling of mucinous breast cancer (2020) (0)
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer (2015) (0)
has shed light on the biological diversity of breast cancer by the identification of (2010) (0)
Abstract 2801: Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin embedded (FFPE) tumor samples using a novel tumor-only sequencing panel with error correction (2022) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
Abstract 4413: CDK6 overexpression promotes resistance to CDK4/6 inhibitors in breast cancer (2019) (0)
MicroArrays comparative genomic hybridisation (aCGH) and response to neoadjuvant chemotherapy (CT) in breast cancer (BC) (2005) (0)
Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas (2019) (0)
Abstract 1470: Ovarian cancer PDXs preserve preexisting genetic oligoclonality (2015) (0)
Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer (2022) (0)
Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice. (2012) (0)
Abstract 2470: Compromised BRCA1-PALB2 interaction is associated with breast cancer risk (2017) (0)
73 Proffered Paper: Glial Cell Line-derived Neurotrophic Factor (GDNF) Signaling as a Target for Endocrine Therapy Resistance in Breast Cancer (2012) (0)
Abstract 1394: Comprehensive clinical and genomic analysis for patients with MYC, MYCN, and MYCL amplified solid tumors (2023) (0)
Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer (2020) (0)
Abstract P3-07-02: Metaplastic breast carcinomas and uterine carcinosarcomas are histologically and genetically related (2019) (0)
Abstract 927: Genomic profiling of metastatic breast cancer identifies the Hippo pathway to be a key determinant of CDK4/6 inhibitor sensitivity (2019) (0)
Abstract 3039: Identification of a novel biomarker of resistance to lapatinib common to both breast and oesophagogastric cancer (2011) (0)
Abstract P2-03-08: Mutational landscape of metaplastic breast carcinomas (2015) (0)
NR4A3 Expression is Consistently Absent in Acinic Cell Carcinomas of the Breast: A Potential Nosologic Shift. (2023) (0)
Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models (2023) (0)
Metaplastic Breast Cancer: Current Understanding and Future Directions (2023) (0)
Abstract 5132: 14-3-3sigma coordinates breast tumor invasion by regulating cytoskeletal dynamics (2010) (0)
Abstract P3-06-07: Recurrent but not pathognomonic fusion genes in mucinous carcinomas of the breast (2019) (0)
Regression-based Deep-Learning predicts molecular biomarkers from pathology slides (2023) (0)
Loss of the BRCA1-PALB2 interaction accelerates p53-associated tumor development in mice (2020) (0)
Abstract 4735: Single-cell sequencing from formalin-fixed paraffin-embedded breast cancers: a powerful tool to address intratumor genetic heterogeneity (2015) (0)
Gene-specific interactions between ultraviolet radiation and melanoma (2016) (0)
Abstract P2-01-02: Capturing intra-tumor genetic heterogeneity in cell-free plasma DNA from patients with oligometastatic breast cancer (2016) (0)
Endometrial cancers in or germline mutations carriers (2019) (0)
Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge (2023) (0)
Abstract 4817: Microsatellite instability status in endometrioid endometrial carcinomas is associated with distinct types and patterns of PI3K pathway mutations (2015) (0)
Abstract 993: Identification of estrogen receptor alpha 1 bound lncRNAs in aggressive breast cancer (2016) (0)
The Genomic Landscape of PALB2-Associated Breast Cancers (2017) (0)
Abstract 2607: The cBioPortal for Cancer Genomics: an open source platform for accessing and interpreting complex cancer genomics data in the era of precision medicine (2017) (0)
Abstract 2971: Whole exome sequencing reveals heterogeneity within lobular carcinoma in situ (LCIS) and clonal selection in the progression to malignant lesions (2015) (0)
How Did We Get There? The Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma (2019) (0)
P1-06-22: Identification of Biomarkers in Breast Cancer for Prediction of Response to PARP Inhibitor Olaparib. (2011) (0)
Abstract LB-335: Loss of function of the BRCA1-PALB2-BRCA2 axis accelerates p53-associated tumorigenesis (2020) (0)
Histopathology would like to thank the following reviewers for their help in 2007: (2007) (0)
Abstract P2-05-01: Single cell sequencing analysis of formalin-fixed paraffin-embedded ductal carcinomas in situ and invasive breast cancers reveals clonal selection in the progression from in situ to invasive disease (2016) (0)
The genomic landscape of metastatic histologic special types of invasive breast cancer (2020) (0)
Abstract 3917: EMSY amplification and overexpression is not associated with defective homologous recombination and does not predict sensitivity to cisplatin or PARP inhibitors (2011) (0)
Abstract A184: Integrative molecular and functional profiling of HER2 amplified breast cancers to identify new gene targets. (2011) (0)
Abstract A239: MPS1 (TTK) kinase inhibition selectively kills aneuploid cells (2009) (0)
234 Clonality analysis of synchronous endometrial and ovarian carcinomas in patients with lynch syndrome (2019) (0)
Abstract 2949: Enabling single cell analysis of copy number variation in breast cancer (2022) (0)
12 Genetic analysis of primary and recurrent adult granulosa cell tumors of the ovary (2019) (0)
Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity. (2013) (0)
Abstract P2-03-09: Benchmarking mutation function prediction algorithms using validated cancer driver and passenger mutations (2015) (0)
Abstract PD8-06: The genomic landscape of metastatic special histologic types of breast cancer (2020) (0)
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer (2012) (0)
Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models (2022) (0)
RESULTS Genomic Features of Advanced , Post-Treatment Breast Cancer (2019) (0)
Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary (2020) (0)
Abstract LB-031: Generation of inducible oncogenic chromosomal translocations using CRISPR-Cas9 genomic editing (2016) (0)
Genetic alterations in pre-invasive lesions (2010) (0)
Emerging therapeutic targets in endometrial (2011) (0)
Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology (2023) (0)
Abstract P4-04-08: Genomic and transcriptomic characterization of papillary carcinomas of the breast (2013) (0)
Abstract PD8-09: Bi-allelic alterations in homologous recombination (HR) DNA repair-related genes as the basis for HR defects in human cancers: A pan-cancer genomics and functional analysis (2018) (0)
situ hybridisation in breast carcinomas monoclonal antibody (SP3) and chromogenic in against Her2 including the novel rabbit Comparative analysis of six different antibodies (2009) (0)
Abstract P6-13-02: The extent of lobular carcinoma in situ (LCIS) at surgical excision predicts for the development of subsequent breast cancer (2015) (0)
Title: HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers Running title: Antitumoral activity of anti-HER2 ADCs in lung cancer (2020) (0)
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy (2022) (0)
A Novel Tumour-Based Test To Identify Breast Cancer Due to BRCA1 and BRCA2 Mutations. (2009) (0)
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination (2021) (0)
Use of topoisomerase II alpha (TOP2A) protein overexpression to predict response to anthracycline-based chemotherapy. (2011) (0)
O18: Tiling path array CGH of breast cancer cell lines and integration with expression profiling (2005) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer (2020) (0)
Abstract P2-09-03: Quantification of HER2 expression and spatial biology using computational pathology: A cross-assay validation study in breast cancer (2023) (0)
The importance of gene-centring microarray data Reply (2010) (0)
Abstract 6421: Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC) (2023) (0)
Abstract 2488: Characterization of gene fusions in paired primary and metastatic samples of breast cancer in the AURORA molecular screening program (2020) (0)
Abstract P4-05-15: Breast cancers with BRCA1 and BRCA2 mutations are associated with specific pathologic features and molecular profiles: Results from a TCGA sub-analysis (2013) (0)
OP-ANNO190436 1417..1427 (2019) (0)
Edinburgh Research Explorer Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer (2018) (0)
Abstract HER2-07: HER2-07 Genomic Characterization of Primary and Metastatic HER2-low Breast Cancers (2023) (0)
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers (2022) (0)
Abstract P2-03-01: Mutational landscape of breast cancers from PALB2 germline mutation carriers (2016) (0)
Abstract 4029: The impact of multiple drug resistance mechanisms on microarray predictive gene signature performance. (2013) (0)
Abstract PD11-02: Subtyping invasive carcinomas and high-risk lesions for machine learning based breast pathology (2022) (0)
Abstract PD1-4: Somatic leukemogenic mutations associated with infiltrating white blood cells in breast cancer patients (2015) (0)
Abstract S4-04: Lobular carcinoma in situ displays intra-lesion genetic heterogeneity and its progression to invasive disease involves clonal selection and variations in mutational processes (2016) (0)
Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73]. (2021) (0)
Abstract PD1-15: The landscape of somatic genetic alterations in breast cancers fromATMgermline mutation carriers (2018) (0)
Abstract 4987: Identification of novel genes and pathways involved in resistance to HER2-targeting agents in breast cancer (2011) (0)
Abstract 5688: RNA-mediated DNA repair: A novel repair pathway in homologous recombination-deficient cancers (2022) (0)
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies (2021) (0)
Abstract 3379: Massively parallel sequencing analysis of breast adenomyoepitheliomas reveals the heterogeneity of the disease and identifies a subset driven byHRAShotspot mutations (2017) (0)
Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes (2017) (0)
Molecular subtypes and emerging therapeutic opportunities (2011) (0)
Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways (2017) (0)
Evaluating the association between clonal hematopoiesis and germline pathogenic and likely pathogenic variants in cancer predisposition genes. (2020) (0)
Abstract GS3-03: Genomic analysis of 733 HER2+ breast cancers identifies recurrent pathways alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities (2022) (0)
Mapping the Molecular Alterations In IGF-Driven Wilms Tumorigenesis – Perilobar Nephrogenic Rests as Non-Obligate Molecular Genetic Precursor Lesions (2008) (0)
O-21 Detection and quantification of microRNAs in laser microdissected formalin-fixed paraffin embedded (FFPE) breast cancer tissues (2010) (0)
Abstract 5076: Integrative genomic and transcriptomic analysis of metaplastic carcinomas of the breast (2012) (0)
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications (2022) (0)
Overcoming the challenges to implementation of artificial intelligence in pathology. (2023) (0)
Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors (2018) (0)
High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer. (2022) (0)
Clinical Trials and Digital Pathology-Toward Quantitative Therapeutic Immunohistochemistry and Tissue Hybridization. (2022) (0)
Abstract P6-03-05: Dual HER2 blockade of an activating driverHER3mutation: A proof of principle study in a metastatic breast cancer patient (2015) (0)
P1-06-14: Topoisomerase II alpha (Top2a) Protein Expression Is a Predictor for Response to Anthracycline-Based Chemotherapy (ATC-CT): Is It Due to Gene Amplification, HER2−Coamplification or a Summation of Pathways Leading to This Highly Proliferative Phenotype? (2011) (0)
Mutational signature analysis of primary and metastatic endometrial cancer reveals associations with molecular subtypes and shifts during tumor progression (2019) (0)
5175 POSTER Bcl2 Expression Predicts Clinical Outcome to Adjuvant Hormone Therapy and Response to Anthracycline-based Chemotherapy in ER+HER2- Breast Cancer (2011) (0)
Abstract P2-10-01: The genomic landscape of breast cancer in African American women (2020) (0)
Abstract P6-06-02: GermlineCDH1mutations in lobular carcinomain situ (2016) (0)
Atypical lobular hyperplasia (2019) (0)
Abstract GS2-01: Discovery and characterization of an estrogen bound LncRNA in late-Stage breast cancer (2018) (0)
Abstract 4258: Benchmarking algorithms for mutation impact prediction using functionally validated missense mutations (2014) (0)
lesionsbreast pathology: columnar cell (2009) (0)
Abstract P4-04-05: Molecular subtyping reveals the heterogeneity of metaplastic breast cancers (2013) (0)
Abstract P5-02-33: Deep learning-based assessment of HER2-low expression on breast cancer H&E digital whole slide images (2023) (0)
Abstract 1692: Single-cell DNA sequencing from frozen endometrial tumors to address clonal evolution of somatic mutations (2022) (0)
OP-JNCI190159 107..110 (2020) (0)
Abstract 3885: Mutational landscape and copy number alterations of mucinous breast carcinoma (2015) (0)
The Role of BRCA1 and BRCA2 in Anticancer Drug Therapy (2013) (0)
Publisher Correction: Homologous recombination DNA repair defects in PALB2-associated breast cancers (2019) (0)
O8: Array CGH Using Whole Genome Amplification Of Fresh Frozen And Formalin-Fixed, Paraffin-Embedded Tumour DNA (2005) (0)
Molecular Genetics of Ductal Carcinoma In Situ and Lobular Carcinoma In Situ (2011) (0)
REVMUT v0.3.0 (2015) (0)
Mechanistic and clinical analysis of Sperm associated antigen 5 (SPAG5) as a novel prognostic, predictive, actionable gene in Breast Cancer (BC). (2015) (0)
Same-Cell Co-Occurrence of RAS Hotspot and BRAF V600E Mutations in Treatment-Naive Colorectal Cancer (2022) (0)
93P An AI-driven computational biomarker from H&E slides recovers cases with low levels of HER2 from immunohistochemically HER2-negative breast cancers (2022) (0)
5030 High resolution array Comparative Genomic Hybridization (aCGH) of breast carcinoma identifies Mouse double minutes 4 (Mdm4) as one of the early genetic changes in breast cancer development – Mdm4 is a new independent prognostic and predictive marker (2009) (0)
Abstract P6-09-01: RAD51B loss-of-function variants confer susceptibility to hereditary breast and ovarian cancers and result in tumors with genomic features of homologous recombination repair defects (2020) (0)
Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype. (2023) (0)
Immune and genomic profiling of small cell carcinomas of the ovary hypercalcemic type (2020) (0)
Abstract P4-08-12: Clinical and Genomic Landscape of Breast Cancers Carrying CCNE1 Amplification (2023) (0)
Abstract P6-07-04: Distinct repertoires of somatic mutations affecting driver genes in mucinous and neuroendocrine carcinomas of the breast (2016) (0)
Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis (2016) (0)
Abstract P4-05-06: Host inflammation and breast cancer molecular subtypes: Updated results from a TCGA sub-analysis (2013) (0)
Phylogenetic Relationship Between Locoregional Recurrences and Distant Metastasis in Breast Cancer (2019) (0)

This paper list is powered by the following services:

Jorge Sérgio Reis‐filho's Academic­Influence.com Rankings

Jorge Sérgio Reis‐filho's Degrees

Why Is Jorge Sérgio Reis‐filho Influential?

Jorge Sérgio Reis‐filho's Published Works

Published Works

Jorge Sérgio Reis‐filho's AcademicInfluence.com Rankings